Endothelial Protection, AT 1 Blockade and Cholesterol-Dependent Oxidative Stress
Open Access
- 4 July 2006
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation
- Vol. 114 (1_suppleme) , I-296-I-301
- https://doi.org/10.1161/circulationaha.105.001313
Abstract
Background— Statins and angiotensin type 1 (AT 1 ) receptor blockers reduce cardiovascular mortality and morbidity. In the Endothelial Protection, AT 1 blockade and Cholesterol-Dependent Oxidative Stress (EPAS) trial, impact of independent or combined statin and AT 1 receptor blocker therapy on endothelial expression of anti-atherosclerotic and proatherosclerotic genes and endothelial function in arteries of patients with coronary artery disease were tested. Methods and Results— Sixty patients with stable coronary artery disease undergoing elective coronary artery bypass grafting (CABG) surgery were randomized 4 weeks before surgery to: (A) control without inhibition of renin-angiotensin system or statin; (B) statin (pravastatin 40 mg/d); (C) AT 1 blockade (irbesartan 150 mg/d); or (D) combination of statin and AT 1 blocker in same dosages. Primary end point was a priori therapy-dependent regulation of an anti-atherosclerotic endothelial expression quotient Q including mRNA expression (in arbitrary units measured by real-time polymerase chain reaction) of endothelial nitric oxide synthase and C-type natriuretic peptide, divided by expression of oxidized low-density lipoprotein receptor LOX-1 and NAD(P)H oxidase subunit gp91phox in left internal mammary arteries biopsies obtained by CABG surgery; 49 patients completed the study. Statin therapy increased lnQ from 3.2±0.4 to 4.4±0.4 significantly versus control. AT 1 blockade showed a trend to increase lnQ to 4.2±0.5. Combination of statin and AT 1 blocker further increased lnQ to 5.1±0.6, but a putative interaction of both therapies in lnQ was not significant. Furthermore, preoperative therapy with statin, AT 1 blocker and their combination improved endothelial function in internal mammary artery rings. Conclusions— Statin and AT 1 blocker therapy independently and in combination improve an anti-atherosclerotic endothelial expression quotient and endothelial function.Keywords
This publication has 16 references indexed in Scilit:
- C-Type Natriuretic Peptide Relaxes Human Coronary Artery Bypass Grafts Preconstricted by Endothelin-1The Annals of Thoracic Surgery, 2005
- Beyond Blood PressureHypertension, 2005
- Hypertension mega-trials with cardiovascular end points: Effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockersAmerican Heart Journal, 2004
- C-type natriuretic peptide in vascular physiology and diseasePharmacology & Therapeutics, 2004
- Should Angiotensin II Receptor Blockers and Statins Be Combined?Circulation, 2004
- The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseasesTrends in Pharmacological Sciences, 2003
- Effects of statins on the vasculature: implications for aggressive lipid management in the cardiovascular metabolic syndromeThe American Journal of Cardiology, 2003
- Inhibition of LOX-1 by Statins May Relate to Upregulation of eNOSBiochemical and Biophysical Research Communications, 2001
- Upregulation of LOX-1 Expression in Aorta of Hypercholesterolemic Rabbits: Modulation by LosartanBiochemical and Biophysical Research Communications, 2000
- Identification and Autoregulation of Receptor for OX-LDL in Cultured Human Coronary Artery Endothelial CellsBiochemical and Biophysical Research Communications, 1998